Synthetic DNA has proven exceptionally powerful in producing high-efficacy candidates for antibody discovery and development. As with all discovery systems, challenges still remain in relation to the time and resources required to produce ideal, high-specificity candidates.
Azenta Life Sciences, formerly GENEWIZ now offers an antibody DNA synthesis service with Ph.D.-level technical support to alleviate these concerns and streamline your antibody discovery research. Trusted by leading research institutions and pharma/biotech companies worldwide, this service provides synthesis and cloning of your antibody heavy/light chain sequences into any custom vector in as few as 6 days, the fastest turnaround time on the market.
|Synthetic Gene Length||Turnaround Time (TAT)|
6-8 Business Days
|751-1500 bp||8-10 Business Days|
|Custom cloning||No Additional TAT|
Advancements in recombinant monoclonal antibody (rAb) technology have led to the development of a variety of engineered antibody molecules for research, diagnosis, and therapy. With over 10 years of expertise in gene synthesis and cloning, Azenta has supported numerous antibody discovery and development projects, including researchers developing broadly anti-virus monoclonal antibodies , bispecific recombinant antibodies , anticancer Fc-engineered human monoclonal antibody [3, 4], and much more.
Recombinant antibodies can be developed using de novo synthesis of recombinant VDJ light chain and heavy chain sequences. Synthetic DNA can be also used in humanized or other recombinant antibodies such as single-chain variable fragment (scFv), single domain antibody (sdAb), fragment antigen binding mAb (Fab), trifunctional antibody, etc.
“I have always had great customer service from Azenta, received great products with a good price. It allows me to do other things in the lab instead of spending time cloning, etc.”
- Researcher from Cincinnati Children's Hospital Medical Center
“Good quality, customer support, and expediated delivery to help me to meet the deadline.”
- Principal Investigator from a top pharmaceutical company
Xiao H, Guo T, Yang M, et al. Light chain modulates heavy chain conformation to change protection profile of monoclonal antibodies against influenza A viruses. Cell Discov. 2019;5:21. Published 2019 Apr 16. doi:10.1038/s41421-019-0086-x
Ahmed M, Lopez-Albaitero A, Pankov D, et al. TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies. JCI Insight. 2018;3(4):e97805. Published 2018 Feb 22. doi:10.1172/jci.insight.97805
 Qi X, Li F, Wu Y, et al. Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity. Nat Commun. 2019;10(1):2141. Published 2019 May 20. doi:10.1038/s41467-019-10088-1
Dahan R, Barnhart BC, Li F, Yamniuk AP, Korman AJ, Ravetch JV. Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement. Cancer Cell. 2016;29(6):820–831. doi:10.1016/j.ccell.2016.05.001